Novo Nordisk to sell weight loss drug Poviztra in India
10/11/2025 06:01
Nov 10 (Reuters) - Novo Nordisk NOVOb.CO has partnered with India's Emcure Pharmaceuticals EMCU.NS to exclusively distribute and market weight-loss drug Poviztra semaglutide injection in the country, the Indian firm said on Monday. (Reporting by Manvi Pant in Bengaluru; Editing by Mrigank Dhaniwala) ((Manvi.Pant@thomsonreuters.com; +918447554364;))
Recent news on Emcure Pharmaceuticals
See all newsIndia's Emcure Pharma rises on Poviztra approval, Motilal initiation with 'buy'
Brief: Emcure Pharmaceuticals Ltd To Expand Use Of Poviztra For Mash Indication Following CDSCO Approval
Brief: Emcure Pharmaceuticals Says Kuber Jagdale, President, API Business, Superannuates
India's Emcure Pharma hits record high after Jefferies raises TP
Brief: Emcure Pharmaceuticals March-Quarter Consol Net Profit 2.43 Billion Rupees